Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study

Amirizadeh et al., Health Science Reports, doi:10.1002/hsr2.1676
Nov 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -3% Improvement Relative Risk Ventilation time -52% ICU time -27% Hospitalization time -24% Remdesivir  Amirizadeh et al.  ICU PATIENTS Is very late treatment with remdesivir beneficial for COVID-19? Retrospective 70 patients in Iran Longer ventilation (p=0.17) and ICU admission (p=0.23), not sig. c19early.org Amirizadeh et al., Health Science Repo.., Nov 2023 Favorsremdesivir Favorscontrol 0 0.5 1 1.5 2+
Retrospective 70 COVID-19 ICU patients, 35 receiving remdesivir plus standard treatment and 35 receiving standard treatment only. No significant differences were found for mortality, hospitalization time, ICU time, or ventilation time.
Gérard, Zhou, Wu, Kamo, Choi show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 3.3% higher, RR 1.03, p = 1.00, treatment 31 of 35 (88.6%), control 30 of 35 (85.7%).
ventilation time, 52.2% higher, relative time 1.52, p = 0.17, treatment mean 7.03 (±8.92) n=35, control mean 4.62 (±5.24) n=35.
ICU time, 27.0% higher, relative time 1.27, p = 0.23, treatment mean 14.03 (±11.55) n=35, control mean 11.05 (±9.1) n=35.
hospitalization time, 24.2% higher, relative time 1.24, p = 0.22, treatment mean 16.11 (±11.52) n=35, control mean 12.97 (±9.65) n=35.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Amirizadeh et al., 1 Nov 2023, retrospective, Iran, peer-reviewed, 5 authors, average treatment delay 8.04 (treatment) 7.45 (control) days. Contact: kharazmkia@lums.ac.ir, md.ghasemazimi@gmail.com.
This PaperRemdesivirAll
The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
Mehran Amirizadeh, Ali Kharazmkia, Kobra Sharifi Abdoli, Hadi Hayati Abbarik, Ghasem Azimi
Health Science Reports, doi:10.1002/hsr2.1676
In 2002, severe acute respiratory syndrome (SARS) first appeared in China. It quickly spread worldwide within 3 months, resulting in the first pandemic of the twenty-first century with a 10% mortality rate. 1 Several unexplained signs and symptoms of acute and chronic pulmonary pneumonia were recorded in Wuhan, China, in late
CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. ETHICS STATEMENT All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/ or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. TRANSPARENCY STATEMENT The lead author Ali Kharazmkia, Ghasem Azimi affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Mehran Amirizadeh 1 Ali Kharazmkia 1, 2 Kobra Sharifi abdoli 3 Hadi Hayati abbarik 4 Ghasem Azimi 5 1 Department of Clinical Pharmacy, School of Pharmacy,
References
Abd-Elsalam, Ahmed, Mansour, Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial, Am J Trop Med Hyg
Antinori, Cossu, Ridolfo, Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in posttreatment hospitalisation status, Pharmacol Res
Chen, Qi, Liua, Clinical progression of patients with COVID-19 in shanghai, China, J Infect
Chokkalingam, Hayden, Goldman, Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States, JAMA Network Open
Grein, Ohmagari, Shin, Compassionate use of remdesivir for patients with severe Covid-19, N Engl J Med
Gupte, Hegde, Sawant, Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database, BMC Infect Dis
Hegazy, Tharwat, Hassan, Kharazmkia, Sharifi Abdoli et al., Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients, J Clin Virol Plus
Hegazy, Tharwat, Hassan, Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients, Open Med
Jalali Farahani, Swann, Razi, Comparison of clinical, laboratory and radiological findings in Iranian elderly and Non-Elderly patients with COVID-19, J Marine Med
Lee, Santarelli, Caine, Schritter, Dietrich et al., Remdesivir for the treatment of severe COVID-19: a community hospital's experience, J Osteopath Med
Long, Xu, Xiao, Epidemiological and clinical characteristics of patients with coronavirus disease -2019 in shiyan city China, Front Cell Infect Microbiol
Mehta Pharmd, Mph, Shyh, A review of remdesivir for COVID-19: data to date, Cardiol Rev
Ohl, Miller, Lund, Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19, JAMA Network Open
Oksuz, Malhan, Gonen, Cost-Effectiveness analysis of remdesivir treatment in COVID-19 patients requiring low-flow oxygen therapy: payer perspective in Turkey, Adv Ther
Padilla, Arquiette, Mai, Singh, Galang et al., Clinical outcomes of COVID-19 patients treated with convalescent plasma or remdesivir alone and in combination at a community hospital in California's central valley, J Pharm Pharm Sci
Paranjape, Husain, Priestley, Koonjah, Watts et al., Early use of remdesivir in patients hospitalized with COVID-19 improves clinical outcomes a retrospective observational study, Infect Dis Clin Pract
Poliseno, Gallo, Cibelli, Efficacy and safety of remdesivir over two waves of the Sars-CoV-2 pandemic, Antibiotics
Rezagholizadeh, Khiali, Sarbakhsh, Entezari-Maleki, Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis, Eur J Pharmacol
Rodriguez-Guerra, Jadhav, Vittorio, Current treatment in COVID-19 disease: a rapid review, Drugs Context
Sheikhi, Mirkazehi, Azarkish, Clinical and demographic characteristics of patients with COVID -19 in iranshahr hospitals, southeastern Iran in 2020, J Marine Med. Spring
Spinner, Gottlieb, Criner, GS-US-540-5774 Investigators Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial, JAMA
Stoeckle, Witting, Kapadia, Marks, Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir, J Med Virol
Talebi, Nematshahi, Tajabadi, Comparison of clinical and epidemiological characteristics of deceased and recovered patients with COVID -19 in Sabzevar, J Mil Med
Van Laar, De Boer, Gombert-Handoko, Guchelaar, Zwaveling, Liver and kidney function in patients with Covid-19 treated with remdesivir, Br J Clin Pharmacol
Viner, Ward, Hudson, Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents, Arch Dis Child
Walker, Siddell, Lefkowitz, Changes to virus taxonomy and the Statutes ratified by the International Committee on Taxonomy of Viruses
Wu, Peng, Huang, Genome composition and divergence of the novel coronavirus (2019-Ncov) originating in China, Cell Host Microbe
Yokoyama, Briasoulis, Takagi, Kuno, Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials, Virus Res
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature
{ 'indexed': {'date-parts': [[2023, 11, 3]], 'date-time': '2023-11-03T01:06:19Z', 'timestamp': 1698973579798}, 'reference-count': 30, 'publisher': 'Wiley', 'issue': '11', 'license': [ { 'start': { 'date-parts': [[2023, 11, 1]], 'date-time': '2023-11-01T00:00:00Z', 'timestamp': 1698796800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 11]]}, 'DOI': '10.1002/hsr2.1676', 'type': 'journal-article', 'created': {'date-parts': [[2023, 11, 2]], 'date-time': '2023-11-02T04:29:24Z', 'timestamp': 1698899364000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive ' 'care unit: A case–control study', 'prefix': '10.1002', 'volume': '6', 'author': [ { 'given': 'Mehran', 'family': 'Amirizadeh', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, School of Pharmacy Lorestan ' 'University of Medical Sciences Khorramabad Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-9081-8065', 'authenticated-orcid': False, 'given': 'Ali', 'family': 'Kharazmkia', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Clinical Pharmacy, School of Pharmacy Lorestan ' 'University of Medical Sciences Khorramabad Iran'}, { 'name': 'Clinical Research Development Center, Shahid Rahimi Hospital ' 'Lorestan University of Medical Sciences Khorramabad Iran'}]}, { 'given': 'Kobra', 'family': 'Sharifi abdoli', 'sequence': 'additional', 'affiliation': [ { 'name': 'Student Research Committee, School of Pharmacy Lorestan ' 'University of Medical Sciences Khorramabad Iran'}]}, { 'given': 'Hadi', 'family': 'Hayati abbarik', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Pharmacoeconomics and Management, School of ' 'Pharmacy Lorestan University of Medical Sciences Khorramabad ' 'Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0002-1657-7352', 'authenticated-orcid': False, 'given': 'Ghasem', 'family': 'Azimi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Internal Medicine, School of Medicine Shahed ' 'University Tehran Iran'}]}], 'member': '311', 'published-online': {'date-parts': [[2023, 11]]}, 'reference': [ {'key': 'e_1_2_12_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41586-020-2012-7'}, { 'key': 'e_1_2_12_3_1', 'unstructured': 'World Health Organization.Coronavirus disease 2019 (COVID‐19): situation ' 'report 73.2020.https://www.who.int/'}, { 'key': 'e_1_2_12_4_1', 'unstructured': 'WalkerPJ SiddellSG LefkowitzEJ et al. Changes to virus taxonomy and the ' 'Statutes ratified by the International Committee on Taxonomy of ' 'Viruses.2020.'}, {'key': 'e_1_2_12_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.chom.2020.02.001'}, { 'key': 'e_1_2_12_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1136/archdischild-2020-320972'}, {'key': 'e_1_2_12_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7573/dic.2020-10-3'}, { 'key': 'e_1_2_12_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/CRD.0000000000000337'}, {'key': 'e_1_2_12_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.7556/jaoa.2020.156'}, { 'key': 'e_1_2_12_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s12325-021-01874-9'}, { 'key': 'e_1_2_12_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2021.14741'}, { 'key': 'e_1_2_12_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.virusres.2020.198137'}, {'key': 'e_1_2_12_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2007016'}, { 'issue': '3', 'key': 'e_1_2_12_14_1', 'first-page': '886', 'article-title': 'Remdesivir efficacy in COVID‐19 treatment: a randomized controlled ' 'trial', 'volume': '106', 'author': 'Abd‐Elsalam SH', 'year': '2021', 'journal-title': 'Am J Trop Med Hyg'}, {'key': 'e_1_2_12_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.18433/jpps31969'}, { 'key': 'e_1_2_12_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/antibiotics10121477'}, { 'key': 'e_1_2_12_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1097/IPC.0000000000001023'}, { 'key': 'e_1_2_12_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jinf.2020.03.004'}, { 'issue': '1', 'key': 'e_1_2_12_19_1', 'first-page': '46', 'article-title': 'Clinical and demographic characteristics of patients with COVID ‐19 in ' 'iranshahr hospitals, southeastern Iran in 2020', 'volume': '3', 'author': 'Sheikhi F', 'year': '2021', 'journal-title': 'J Marine Med. Spring'}, {'key': 'e_1_2_12_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fcimb.2020.00284'}, { 'issue': '6', 'key': 'e_1_2_12_21_1', 'first-page': '509', 'article-title': 'Comparison of clinical and epidemiological characteristics of deceased ' 'and recovered patients with COVID ‐19 in Sabzevar', 'volume': '22', 'author': 'Talebi S', 'year': '2020', 'journal-title': 'J Mil Med'}, { 'key': 'e_1_2_12_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.phrs.2020.104899'}, { 'issue': '4', 'key': 'e_1_2_12_23_1', 'first-page': '216', 'article-title': 'Comparison of clinical, laboratory and radiological findings in Iranian ' 'elderly and Non‐Elderly patients with COVID‐19', 'volume': '2', 'author': 'Jalali Farahani A', 'year': '2021', 'journal-title': 'J Marine Med'}, {'key': 'e_1_2_12_24_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.27280'}, {'key': 'e_1_2_12_25_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/bcp.14831'}, { 'key': 'e_1_2_12_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejphar.2021.173926'}, {'key': 'e_1_2_12_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.16349'}, { 'key': 'e_1_2_12_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jamanetworkopen.2022.44505'}, { 'key': 'e_1_2_12_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12879-021-07004-8'}, {'key': 'e_1_2_12_30_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1515/med-2023-0768'}, { 'key': 'e_1_2_12_31_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jcvp.2023.100151'}], 'container-title': 'Health Science Reports', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1002/hsr2.1676', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 11, 2]], 'date-time': '2023-11-02T10:34:30Z', 'timestamp': 1698921270000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1002/hsr2.1676'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 11]]}, 'references-count': 30, 'journal-issue': {'issue': '11', 'published-print': {'date-parts': [[2023, 11]]}}, 'alternative-id': ['10.1002/hsr2.1676'], 'URL': 'http://dx.doi.org/10.1002/hsr2.1676', 'relation': {}, 'ISSN': ['2398-8835', '2398-8835'], 'subject': ['General Medicine'], 'container-title-short': 'Health Science Reports', 'published': {'date-parts': [[2023, 11]]}, 'assertion': [ { 'value': '2023-06-14', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-10-17', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2023-11-01', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit